Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Protocol length
Executive summary RGA has quantified the expected mortality and morbidity impacts of incretin-based drugs, including GLP-1s, approved as anti-obesity medications (AOMs) and diabetes treatments in the US, UK, Canada, and Hong Kong
Conoce los nuevos medicamentos, avances y su impacto potencial en el control de peso
Reflecting the fact that GLP-1 receptors have been found to be substantially more abundant in the human lung than other organs, GLP-1 drugs are now also being explored for the treatment of acute and chronic pulmonary disease
US$ 26.29
US$ 26.66
.webp)
US$ 22.40
US$ 22.88
US$ 23.50
US$ 29.89
US$ 26.91
